|
|
|
|
|
|
| |
| Review Period Set for Kalbitor |
| 05/02/2012 |
| |
|
Federal Register Notice: FDA has determined the regulatory review period for Dyax Corp.’s Kalbitor (ecallantide) is 2,855 days for extending a patent which claims the human biological product. Kalbitor is indicated for treating acute attacks of hereditary angioedema in patients 16 years of age and older. To view this notice, click here. |
| |
|
| |
| |
Any copying or electronic transfer without written permission is strictly prohibited and will result
in termination of service and prosecution under the federal Copyright Act.
To gain permission to copy this article log on to http://www.copyright.com.
|
|
RSS
